Skip to main content

Table 1 Clinicopathological description of male breast cancers in this study

From: BRCA2 carriers with male breast cancer show elevated tumour methylation

Feature
Age (years) Median = 62.5 Range: 30–85
Mutation carrier status
BRCA1 3 5.0%
BRCA2 25 41.7%
BRCAX 32 53.3%
Size (mm) Median = 17 Range: 2–50
Histological subtype
 Invasive carcinoma - no special type (IC-NST) 46 76.7%
 Invasive papillary carcinoma 8 13.3%
 IC-NST with areas of micropapillary 4 6.7%
 Invasive lobular carcinoma 2 3.3%
Grade
 1 2 3.3%
 2 30 50.0%
 3 28 46.7%
DCIS
 Present 41 68.3%
 Absent 15 25.0%
 Unknown 4 6.7%
Nodal Status
 N0 28 46.7%
 N1 20 33.3%
 Nx 12 20.0%
Paget’s Disease
 Present 8 13.3%
 Absent 44 73.3%
 Unknown 8 13.3%
ER status (Allred score)   
 Negative (0–4/8) 2 3.3%
 Positive (5–8/8) 58 96.7%
PgR status (allred score)
 Negative (0–4/8) 8 13.3%
 Positive (5–8/8) 52 86.7%
HER2 (SISH)
 Amplified 5 8.3%
 Non-amplified 55 91.7%
Phenotype
 Luminal 54 90.0%
 HER2 5 8.3%
 Basal 1 1.7%